# Allarity Therapeutics, Inc.: Form 10-Q for the period ended Jun 30, 2025

- Company: [Allarity Therapeutics, Inc.](/companies/allr.md) (CIK 1860657)
- Form: 10-Q
- Filed: 2025-08-15
- Accepted by EDGAR: Aug 15, 2025, 16:30 ET
- Period: 2025-06-30
- Accession: 0001437749-25-027146
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1860657/000143774925027146/allr20250630_10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1860657/000143774925027146/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2025-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Research and development | 3 months, 2025-04-01 to 2025-06-30 | $2.3m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2025-01-01 to 2025-06-30 | $3.7m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2025-04-01 to 2025-06-30 | −$4.1m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2025-01-01 to 2025-06-30 | −$7.2m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2025-04-01 to 2025-06-30 | $12.0k | us-gaap:InterestExpenseNonoperating |
| Interest expense | 6 months, 2025-01-01 to 2025-06-30 | $69.0k | us-gaap:InterestExpenseNonoperating |
| Income tax | 3 months, 2025-04-01 to 2025-06-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2025-01-01 to 2025-06-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2025-04-01 to 2025-06-30 | −$2.3m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2025-01-01 to 2025-06-30 | −$5.1m | us-gaap:NetIncomeLoss |
| Basic EPS | 3 months, 2025-04-01 to 2025-06-30 | −$0.15 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2025-01-01 to 2025-06-30 | −$0.38 | us-gaap:EarningsPerShareBasic |
| Operating cash flow | 6 months, 2025-01-01 to 2025-06-30 | −$8.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Share repurchases | 6 months, 2025-01-01 to 2025-06-30 | $2.6m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2025-06-30 | $17.8m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2025-06-30 | $20.9m | us-gaap:AssetsCurrent |
| Total assets | at 2025-06-30 | $21.2m | us-gaap:Assets |
| Current liabilities | at 2025-06-30 | $9.0m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2025-06-30 | $9.0m | us-gaap:Liabilities |
| Shareholders' equity | at 2025-06-30 | $12.2m | us-gaap:StockholdersEquity |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1860657/000143774925027146/allr20250630_10q.htm

Filed Aug 15, 2025.
Source: SEC EDGAR, the filing index for accession 0001437749-25-027146. Last ingested by Listed: Nov 2, 2026, 08:01 ET. No prices; not investment advice.